Classic pantothenate kinase-associated neurodegeneration
disease diseaseOn this page
Also known as NBIA1, classic formneurodegeneration with brain iron accumulation type 1, classic formPKAN, classic form
Summary
Classic pantothenate kinase-associated neurodegeneration (MONDO:0016304) is a disease. A subtype of pantothenate kinase-associated neurodegeneration — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Phenotypes (HPO): 28
Clinical features
Signs & symptoms
Clinical features (HPO)
28 HPO clinical features (Orphanet curated; top 28 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001288 | Gait disturbance | Very frequent (80-99%) |
| HP:0000157 | Abnormality of the tongue | Frequent (30-79%) |
| HP:0000510 | Rod-cone dystrophy | Frequent (30-79%) |
| HP:0000543 | Optic disc pallor | Frequent (30-79%) |
| HP:0000580 | Pigmentary retinopathy | Frequent (30-79%) |
| HP:0001257 | Spasticity | Frequent (30-79%) |
| HP:0001260 | Dysarthria | Frequent (30-79%) |
| HP:0001347 | Hyperreflexia | Frequent (30-79%) |
| HP:0002015 | Dysphagia | Frequent (30-79%) |
| HP:0002359 | Frequent falls | Frequent (30-79%) |
| HP:0002454 | Eye of the tiger anomaly of globus pallidus | Frequent (30-79%) |
| HP:0002533 | Abnormal posturing | Frequent (30-79%) |
| HP:0002540 | Inability to walk | Frequent (30-79%) |
| HP:0002659 | Increased susceptibility to fractures | Frequent (30-79%) |
| HP:0003552 | Muscle stiffness | Frequent (30-79%) |
| HP:0007018 | Attention deficit hyperactivity disorder | Frequent (30-79%) |
| HP:0007325 | Generalized dystonia | Frequent (30-79%) |
| HP:0012675 | Iron accumulation in brain | Frequent (30-79%) |
| HP:0030051 | Tip-toe gait | Frequent (30-79%) |
| HP:0100543 | Cognitive impairment | Frequent (30-79%) |
| HP:0000298 | Mask-like facies | Occasional (5-29%) |
| HP:0001263 | Global developmental delay | Occasional (5-29%) |
| HP:0001824 | Weight loss | Occasional (5-29%) |
| HP:0002179 | Opisthotonus | Occasional (5-29%) |
| HP:0011951 | Aspiration pneumonia | Occasional (5-29%) |
| HP:0012735 | Cough | Occasional (5-29%) |
| HP:0000618 | Blindness | Very rare (<1-4%) |
| HP:0001250 | Seizure | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | classic pantothenate kinase-associated neurodegeneration |
| Mondo ID | MONDO:0016304 |
| Orphanet | 216866 |
| UMLS | C5679812 |
| MedGen | 1826057 |
| GARD | 0017114 |
| Is cancer (heuristic) | no |
Also known as: NBIA1, classic form · neurodegeneration with brain iron accumulation type 1, classic form · PKAN, classic form
Disease family
This is a subtype of pantothenate kinase-associated neurodegeneration. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › mineral metabolism disease › iron metabolism disease › neurodegeneration with brain iron accumulation › pantothenate kinase-associated neurodegeneration › classic pantothenate kinase-associated neurodegeneration
Related subtypes (1): atypical pantothenate kinase-associated neurodegeneration
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.